The antibodies in regeneron and bamlanivimab are directly targeted at Corona virus. Convalescent plasma is just the plasma from infected patients on the hope there is sufficient antibodies. The infusions of monoclonal antibodies insure the proper concentration of nothing except what is targeted at Corona virus. So the monoclonal are better in terms of directed therapeutic and quantity.
Are they prepared from recovered patients or synthetically?
I seem to remember an article that bamlanivimab is no longer to be used.
Sorry. Engineer and interested in everything.